Effect of montelukast sodium chewable tablet in the treatment of children with bronchial asthma
10.7683/xxyxyxb.2017.12.019
- VernacularTitle:孟鲁司特钠咀嚼片治疗儿童支气管哮喘疗效观察
- Author:
bing Dao SONG
1
Author Information
1. 随州市妇幼保健院儿内科
- Keywords:
bronchial asthma;
children;
montelukast sodium chewable tablet;
interleukin-8;
nuclear factor-κB
- From:Journal of Xinxiang Medical College
2017;34(12):1118-1120,1124
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and mechanism of montelukast sodium chewable tablet in the treatment of children with bronchial asthma.Methods A total of 180 children with bronchial asthma were selected from March 2015 to June 2016 in Suizhou Maternal and Child Health Hospital.The children were divided into montelukast group (n =120) and control group (n =60) according to the therapeutic method.The children in the control group were treated with conventional treatment,including budesonide atomization,expectorant,maintaining electrolyte and acid-base balance,anti-infective therapy,β-agonists and so on.The children in the montelukast group were treated with montelukast sodium chewable tablet on the basis of conventional treatment.The children in the two groups were treated for 14 days.The clinical effect,lung function and the levels of serum nuclear factor-κB (NF-κB) and interleukin-8 (IL-8) were compared between the two groups.Results There was no significant difference in serum NF-κB and IL-8 levels between the two groups before treatment (P ＞ 0.05).The levels of serum NF-κB and IL-8 after treatment were significantly lower than those before treatment in the two groups (P ＜ 0.05).The levels of serum NF-κB and IL-8 in the montelukast group were significantly lower than those in the control group (P ＜ 0.05).There was no significant difference in the forced expiratory volume in first second (FEV1),peak expiratory flow (PEF) and percentage of FEV1 to forced vital capacity (FEV1％) between the two groups before treatment (P ＞ 0.05).The FEV1,PEF and FEV1％ after treatment were significantly higher than those before treatment in the two groups (P ＜ 0.05).The FEV1,PEF and FEV1％ in the montelukast group were significantly higher than those in the control group after treatment (P ＜ 0.05).The total effective rate in montelukast group and control group was 95.83 ％ (115/120) and 71.67 ％ (43/60) respectively,the total effective rate in montelukast group was significantly higher than that in control group (x2 =6.989,P ＜ 0.05).The incidence of adverse reactions in montelukast group and control group was 10.83％ (13/120) and 11.67％ (7/60) respectively,there was no significant difference in the incidence of adverse reactions between the two groups (x2 =0.345,P ＞ 0.05).There was no serious adverse reaction in the two groups during the treatment.Conclusion Montelukast sodium chewable tablet can significantly reduce the respiratory tract inflammatory reaction,improve the lung function,improve the clinical symptoms and have better safety in children with bronchial asthma.
